Authors Yang, Z. ; Zhong, S. ; Yang, Y. ; Maitz, M.F. ; Li, X. ; Tu, Q. ; Qi, P. ; Zhang, H. ; Qiu, H. ; Wang, J. ; Huang, N.
Title Polydopamine-mediated ling-term elution of the direct thrombin inhibitor bivalirudin from TiO2 nanotubes for improved vascular biocompatibility
Date 25.08.2014
Number 44045
Abstract Thrombosis and restenosis are two major complications associated with current commercial vascular stents. In situ regeneration of a healthy endothelium has been recognized as a promising strategy to address these issues. Numerous strategies have been explored for this goal. However, in most cases they only focused on enhancing endothelial cell growth, ignoring antithrombotic requirements and the competition between the smooth muscle cells (SMCs) and the endothelial cells (ECs) in their growth. This resulted in non-satisfying clinical results. In this study, we created a multifunctional surface that meets the need of antithrombosis and re-endothelialization. A nanotubular titanium oxide (TiO2) system has been developed, which elutes the direct thrombin inhibitor bivalirudin (BVLD); polydopamine (PDAM) is used to tailor the surface functionality of TiO2 nanotubes (NTs) for controlling the elution of BVLD. PDAM-functionalized TiO2 NTs controls the BVLD more than two months. BVLD eluted from NTs was bioactive and showed a substantial inhibitory effect on thrombin bioactivity, platelet adhesion and activation. Additionally, the BVLD-eluting nanotubular TiO2 system has high selectivity to enhance human umbilical vein endothelial cell (HUVEC) growth while it inhibits human umbilical artery smooth muscle cell (HUASMC) proliferation. Our design strategy for the BVLD-eluting nanotubular TiO2 system creates a favorable microenvironment for durable thromboresistance and promotion of re-endothelialization, and thereby it is suitable for the long-term treatment of cardiovascular disease.
Publisher Journal of Materials Chemistry B
Citation Journal of Materials Chemistry B 2 (2014) 6767-6778

Back to list